Pharming Group N.V. - ADR Forecast, price target & analysts
Pharming Group N.V. - ADR Target price 2025 - Analyst rating & recommendation
Pharming Group N.V. - ADR Classifications & Recommendation:
Pharming Group N.V. - ADR Price Target
| Target Price | $2.25 |
| Price | $17.15 |
| Deviation |
86.90%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Pharming Group N.V. - ADR 2026 .
The average Pharming Group N.V. - ADR target price is $2.25.
This is
86.90%
register free of charge
$2.98
82.61%
register free of charge
$1.64
90.44%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Pharming Group N.V. - ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2026 of
86.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 297.20 | 349.81 |
| 21.15% | 17.70% | |
| EBITDA Margin | 2.51% | 4.23% |
| 157.26% | 68.75% | |
| Net Margin | -3.98% | 4.59% |
| 7.36% | 215.22% |
8 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2025 . The average Pharming Group N.V. - ADR sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2025. The average Pharming Group N.V. - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Pharming Group N.V. - ADR Analysts have issued a net profit forecast 2025. The average Pharming Group N.V. - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.02 | 0.02 |
| 0.00% | 200.00% | |
| P/E | 744.65 | |
| EV/Sales | 3.10 |
Current Pharming Group N.V. - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Aug 21 2025 |
| PORTZAMPARC BNP PARIBAS |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Jun 30 2025 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Jun 29 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Sep 03 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Aug 21 2025 |
|
Locked
PORTZAMPARC BNP PARIBAS:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Jun 30 2025 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Jun 29 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
May 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
